Lupus & antiphospholipid syndrome
Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study
Authors' conclusion
In general, during treatment with belimumab, immunological and biochemical indices improved in SLE patients, urinary protein levels were reduced in LN patients, and the rate of renal function remission was effectively increased; At the same time, the use of belimumab is associated with a low frequency of side effects, good overall tolerability and a favorable safety profile.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (56 with lupus nephritis (LN)) at a single hospital, March 2020 to September 202256 with LN
- Participants
- 101 patients
- Outcome
- LLDAS and DORIS remission
- Follow-up
- 52 weeks
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Achieved Lupus Low Disease Activity State (LLDAS)
55.4%
Achieved DORIS remission
23.8%
Observational data: associations, not effects.
Further findings
Renal response in LN · 52 weeks
- Complete remission (CR)
- 73.2%
- Partial remission (PR)
- 16.1%
Laboratory indices and GC dose vs pretreatment · 52 weeks
- Complement levels increased significantly
- P < 0.05
- 24-hour urine protein and daily GC dose decreased vs pretreatment
- P < 0.05
Safety
- Adverse reactions in patients treated with belimumab
- 15 (14.9%)
- All of which normalized after symptomatic treatment
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →